Notch genes encode a family of transmembrane proteins that are involved in many cellular processes such as differentiation, proliferation, and apoptosis. Although it is well established that all four Notch genes can act as oncogenes, the mechanism by which Notch proteins transform cells remains unknown. 
There is now significant evidence that constitutively active alleles of all four Notch genes are involved in oncogenesis (2, 3, 14, 37, 42, 48) . Furthermore, the importance of Notch mutations in the development of neoplastic diseases is underscored by studies of proviral-insertional mutagenesis. Infection of mice carrying a c-myc, E2A-PBX1, or erbB2 transgene with replication-competent retroviruses results in proviral integrations into the Notch1 locus, generating constitutively active alleles of Notch1 (9, 11, 15) . In T-cell acute lymphoblastic leukemia, the chromosomal translocation t(7;9)(q34;q34.3) joins a portion of the T-cell receptor gene to the Notch1 gene, resulting in the aberrant expression of truncated Notch proteins (10) . Although this is the only known genetic alteration involving the Notch1 locus in a human cancer, aberrant expression of Notch1, Notch2, and Notch3 has been observed in human cancers of different origins (1b, 6, 40, 56) . Truncation of the extracellular sequences from Notch proteins results in constitutively active forms (termed Notch ic ) that are no longer tethered to the plasma membrane and localize primarily in the nucleus. Mutant forms of Notch1 and Notch2 analogous to those found in cells harboring a t(7;9)(q34;q34.3) translocation (Notch1 ic and Notch2 ic , respectively) transform an E1A-immortalized baby rat kidney cell line (RKE). These transformed cells form colonies in semisolid media and are tumorigenic in nude mice (3) . The molecular mechanism by which Notch induces neoplastic transformation is not known. However, we have recently shown that both nuclear localization and transcriptional activation are requirements for Notch ic -induced transformation (23, 43) .
The current model for Notch signaling proposes that, following ligand binding, Notch is proteolytically processed, releasing the intracellular domain (Notch ic ) from the plasma membrane, which subsequently translocates to the nucleus. Once in the nucleus, Notch ic interacts with CSL [acronym for CBF1, Su(H) and Lag-1] (22, 26, 29, 44, 49) . It has been shown that CSL interacts with SMRT and CIR, which form complexes with histone deacetylases, suggesting a role for CSL in the repression of transcription (20, 25, 57) . It has been proposed that Notch ic binds to CSL, displacing the repressor complex and forming an activating complex, thereby converting CSL into an activator of transcription. It has been shown that Notch is able to interact with the histone acetylases PCAF and GCN5 by two-hybrid analysis, suggesting that a possible mechanism of induction of transcription of CSL target genes may involve chromatin remodeling (13, 19, 26, 30, 33) .
A hallmark of neoplastic transformation is uncontrolled cellular proliferation. Deregulation of components of the cell cycle machinery that control the transition from the G 1 to the S phase of the cell cycle is frequently involved in tumorigenesis. As a consequence, cells proliferate independently of extracellular queues. For example, tumor cells generally do not respond to growth-inhibitory signals induced by contact with neighboring cells and grow with a reduced dependence on serum in media (45, 52) . Cyclin D1 has been shown to play a critical role in the control of the G 1 /S transition of the cell cycle. The level of expression of cyclin D1 is crucial for its function, and it is finely regulated. Cyclin D1 accumulation depends on the activation of transcription of the gene and is induced by many mitogenic signals. Cyclin D1 downregulation is, instead, mediated by a rapid degradation of the protein following ubiquitination (7, 8, 27, 46, 47) . Overexpression of cyclin D1 has been shown to be associated with alterations of cell cycle kinetics and the acceleration of G 1 phase, suggesting that cyclin D1 can directly induce cellular proliferation. Cells overexpressing cyclin D1 show a reduced dependence on serum and are, therefore, able to proliferate in lower concentrations of serum. However, cells overexpressing cyclin D1 grow in a reduced amount of serum with lower kinetics than those observed in cells in the presence of normal levels of serum, indicating that cyclin D1 is not able to fully compensate for the absence of serum-derived mitogens (36, 39, 58) . Cyclin D1 alone is not able to induce complete cellular transformation. Expression of cyclin D1 in both primary and immortalized rodent cells did not result in the formation of foci but produced morphological transformation accompanied by acceleration of growth (18, 24) . However, in several human tumors aberrant expression of cyclin D1 has been detected as a consequence of amplification or rearrangement of the gene and it has recently been suggested that cyclin D1 is likely to play an important role in transformation mediated by several other oncogenes, indicating a key role for cyclin D1 in tumorigenesis (16, 34, 41, 45, 50) .
Previously, we demonstrated that Notch ic proteins transform RKE cells and that transformation can be finely modulated by hormone activation of inducible Notch ic -estrogen receptor (ER) chimeras (3, 23, 43 (23, 43) . In order to obtain the clonal RKE cell line expressing Ras V12 (RKERas), RKE cells were transfected with ZipNeo Kras4B V12 (kindly provided by C. J. Der) using lipofectamine (Gibco-BRL). Isolated neomycin-resistant colonies were selected, and cell lines were propagated in Dulbecco's modified Eagle's medium supplemented with 10% FBS and 400 g of neomycin per ml.
RT-PCR analysis. Total RNA was extracted from confluent cultures using Trizol Reagent (Life Technologies) according the manufacturer's specifications. cDNA was synthesized from 2 g of RNA using Moloney murine leukemia virus reverse transcriptase (RT; Promega) according to the manufacturer's protocol. One microliter of the 20-l cDNA sample was used for PCR amplification. PCRs were performed in a 50-l mixture containing a 0.5 M concentration of each gene-specific primer, 1.5 mM MgCl 2 , 200 M each deoxynucleoside triphosphate, 1ϫ PCR buffer (Hybaid), 0.2 U of DNA polymerase (Hybaid), and 0.2 Ci of [␣-
32 P]dCTP. Sequences of primers used to specifically amplify endogenous rat mRNA for cyclin D1, cyclin E, E2F-1, and Cdc25A are as described in the work of Vigo et al. (51) . The sequences of rat ␤-actin primers used for PCR are 5Ј-CGATATCGCTGCGCTCGTCGTCGAC-3Ј and 5Ј-GGCCAGGATAG AGCCACCAATCCAC-3Ј. In order to perform semiquantitative PCR, we used cycling parameters that displayed a linear range of amplification for each set of primers, determined by amplifications of serial dilutions of cDNAs. Amplified PCR products were separated on a 4% polyacrylamide gel in 1ϫ Tris-acetate-EDTA buffer. Quantification of the mRNA levels was performed using a Storm PhosphorImager (Molecular Dynamics) and Image Quant analysis software. Northern blot analysis. Total RNA was isolated as described for RT-PCR. Thirty micrograms of RNA per sample was electrophoresed on a 1% agarose-6.5% formaldehyde gel and transferred overnight onto a nylon filter. The hybridization was performed overnight at 65°C using cyclin D1 and ␤-actin cDNAs radiolabeled with [␣-32 P] dCTP using a randomly primed labeling kit (New England Biological Laboratories). The hybridization mixture contained 6ϫ SSC (1ϫ SSC is 0.15 NaCl plus 0.015 sodium citrate), 5ϫ Denhardt's solution, 0.5% sodium dodecyl sulfate (SDS), and 0.1 mg of salmon sperm DNA per ml. The blots were washed under high-stringency conditions, and messages were visualized by autoradiography.
CDK2 assay. To measure CDK2 activity, clonal RKE cell lines were grown to confluence in 100-mm-diameter plates. Following serum starvation in medium containing 0.1% FBS for 48 h, cells were incubated overnight in medium containing either 0.1 or 10% FBS in the presence or absence of 1 M 4-hydroxytamoxifen (OHT). Samples not treated with hormone received an equal volume of a 100% ethanol vehicle. Cells were lysed as described in the work of Matsushime et al. (35) . CDK2 was immunoprecipitated from precleared lysates with an anti-CDK2 polyclonal antibody (kindly provided by K. Keyomarsi). The immunocomplexes were collected and assayed for kinase activity as previously described (4). Labeled proteins were separated by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography. Quantitative analysis was performed as described for RT-PCR.
Thymidine incorporation. Clonal RKE cell lines were seeded in 24-well plates at 80% confluence. EMSA. 293T cells were transiently transfected, using BES-modified calcium phosphate precipitation, with 5 g of either green fluorescent protein (GFP) or a hemagglutinin (HA)-tagged CSL expression plasmid (CBF1-HA; kindly provided by P. D. Ling). (To be consistent with current literature, we refer to this protein as CSL throughout this paper.) After 48 h, cells were lysed and protein expression was assayed by Western immunoblotting as previously described (43), using an anti-CSL antibody (kindly provided by E. Bresnick) or an anti-HA tag antibody (HA-probe, Y-11; Santa Cruz). DNA binding reactions were performed according to the method of Lam and Bresnick (32) by incubating 20 g of total cell extract with 60 fmol of 32 P-labeled duplex oligonucleotides containing CSL binding sites. DNA-protein complexes were resolved on a 6.5% nondenaturing polyacrylamide gel in 0.75ϫ Tris-acetate-EDTA buffer. The complete sequence of the 5Ј-3Ј strand of the oligonucleotides used for electrophoretic mobility shift assays (EMSA) is shown in Fig. 5A . The putative CSL binding site, GCTGAG AT, is in the center of the oligonucleotide and is flanked at both the 5Ј and 3Ј ends by 10 residues of a sequence derived from the human or rat cyclin D1 promoter. The mutant site used in our experiments, GCCTGCAG, was previously shown not to bind CSL (31) . As a control for DNA binding experiments, we also used an oligonucleotide that contains three copies of a high-affinity CSL binding sequence, GTGGGAA, spanned by 10 random residues (JK3X). The complete sequence of the wild-type (wt) JK3X oligonucleotide is 5Ј-CGTGGG AAATTTGACTTCGTGGGAAATTTGACTTCGTGGGAA-3Ј, and that of the mut JK3X is 5Ј-CTCTGGAAATTTGACTTCTCTGGAAATTTGACTTCT CTGGAA-3Ј, where the CSL binding site is underlined and the mutated residues are shown in boldface.
RESULTS

Hormone-dependent activation of Notch ic
-ER chimeras induces cyclin D1 mRNA transcription. Recently we created inducible Notch ic chimeric proteins by fusing the intracellular portion of Notch to the estrogen binding domain of the human ER. We reported that the activation of Notch ic -ER chimeras can be finely modulated by treatment with OHT and that hormone activation of Notch ic -ER proteins induces transfor-mation of RKE cells in a dose-dependent manner (43) . Transformed cells are characterized by uncontrolled cellular proliferation. An important checkpoint of cellular proliferation is the transition from the G 1 to the S phase of the cell cycle. A fundamental mechanism to control the G 1 /S transition is the regulation of expression of cell cycle machinery components. In order to determine if Notch ic -induced transformation involves transcriptional activation of genes encoding factors known to play a role in this transition, we analyzed the mRNA levels of the cyclin D1, cyclin E, Cdc25A, and E2F-1 genes by RT-PCR.
Total RNA was extracted from clonal RKE cell lines expressing either Notch ic -ER chimeras (ER-N ic and N ic -ER) or the estrogen binding domain (ER) alone (43) . Following serum deprivation for 48 h, cells were treated for 5 h with or without 1 M OHT in medium containing either a low (0.1%) or a full (10%) concentration of serum. Hormone activation of Notch ic -ER chimeras induced the accumulation of cyclin D1 mRNA in a low concentration of serum (Fig. 1A) . In cells expressing the ER-N ic chimera, the level of cyclin D1 mRNA detected in samples treated in 0.1% serum plus 1 M OHT was approximately sevenfold higher than the level detected in a low concentration of serum in the absence of OHT. Under the same experimental conditions, cells expressing the N ic -ER chimeric protein displayed a four-fold increase in the induction of cyclin D1 transcription. The level of cyclin D1 induced by serum alone was approximately threefold higher than the basal level detected in 0.1% serum in the absence of OHT. However, the induction of cyclin D1 transcription by serum in the presence of OHT was twofold higher than the induction by serum alone (Fig. 1) . In control cells expressing ER alone, cyclin D1 mRNA was detectable only upon stimulation with 10% serum. OHT had no effect on cyclin D1 mRNA expression (Fig. 1A) . Northern blot analysis of total RNA extracted from samples treated under the experimental conditions described above confirmed the induction of cyclin D1 transcription by hormone-activated Notch ic -ER chimeras, validating the results observed by RT-PCR (Fig. 1B) . We did not observe an increase in mRNA levels for cyclin E, E2F-1, and Cdc25A upon hormone activation of Notch ic -ER (Fig. 1A) , indicating that hormone-activated Notch ic -ER chimeras specifically induced transcription of cyclin D1. Furthermore, our data show that the activation of cyclin D1 induced by Notch ic -ER proteins is independent of the induction by other serum growth factors.
Induction of cyclin D1 expression by Notch ic -ER proteins is direct. It has been reported that the induction of cyclin D1 transcription by serum typically requires from 3 to 4 h (5, 21, 53, 54). In RKE cells, induction of cyclin D1 mRNA by serum is detectable in approximately 5 h (Fig. 2A) . In contrast, cyclin D1 mRNA induced by hormone activation of Notch ic -ER proteins can be detected in 1 h (Fig. 2) . The rapid induction of cyclin D1 mRNA suggests that Notch ic can activate cyclin D1 transcription through a direct mechanism.
In order to determine if the accumulation of cyclin D1 mRNA induced by hormone-activated Notch ic -ER chimeras was independent of de novo synthesis of secondary transcription factors, we analyzed cyclin D1 expression in cells treated with the protein synthesis inhibitor cycloheximide (CHX). RT-PCR was performed on RNA samples extracted from cells expressing Notch ic -ER proteins induced for 1 or 4 h under conditions similar to those described above but in the presence or absence of 15 g of CHX per ml. CHX had no effect on the induction of cyclin D1 transcription by Notch ic -ER proteins. The levels of cyclin D1 mRNA detected were similar in the presence and absence of the inhibitor (Fig. 2B ). Under these experimental conditions 99% of protein synthesis was inhibited, as determined by [ 35 S]methionine incorporation (data not shown). These data indicate that the induction of cyclin D1 transcription mediated by hormone-activated Notch ic -ER proteins is direct and does not require de novo synthesis of secondary transcription factors.
Nontransforming Notch ic proteins fail to activate cyclin D1 transcription. We have previously described mutations that affect the ability of Notch ic proteins to induce the transformation of RKE cells (23) . In order to determine if the transforming ability of Notch ic proteins depends on their ability to activate cyclin D1 transcription, we extracted total RNA from clonal RKE cell lines expressing Notch ic and two different Notch ic mut proteins and analyzed cyclin D1 mRNA by RT-PCR. Clonal RKE cells expressing Notch ic displayed a level of cyclin D1 mRNA sevenfold higher than the level detected for the parental RKE cell line. In contrast, the level of cyclin D1 mRNA detected in the RKE clonal line expressing N ic⌬R was only threefold higher than the level in RKE cells (Fig. 3) . N ic⌬R lacks the primary binding domain for CSL (RAM domain). We have previously shown that N ic⌬R displays a weaker ability to form foci than that of Notch ic , likely due to a diminished ability to interact with CSL and activate transcription (23) . In contrast, N ic⌬2105-2114 failed to induce cyclin D1 mRNA expression. The level of cyclin D1 mRNA detected in cells expressing N ic⌬2105-2114 was similar to the basal level detected in RKE cells (Fig. 3) . N ic⌬2105-2114 has a 10-amino-acid deletion that abolishes its ability to transform cells and to activate transcription from a reporter construct containing CSL high-affinity binding sites, although it is still able to bind CSL (23). As described for Notch ic -ER chimeras (Fig. 1A) , transcriptional activation of cyclin D1 by Notch ic was specific, since all clonal RKE cell lines express similar constitutive levels of cyclin E, E2F-1, and Cdc25A mRNA (Fig. 3) . For comparison, we determined the level of cyclin D1 mRNA in RKE cells transformed by Ras V12 (RKE-Ras). RKE-Ras expressed cyclin D1 to a level 20-fold higher than the level observed in RKE cells. Here we show that Notch ic proteins that are incapable of activating cyclin D1 transcription fail to transform cells, suggesting that the mechanism of transformation mediated by Notch ic requires the induction of cyclin D1 expression.
Hormone activation of Notch ic -ER chimeras induces CDK2 activity and promotes entry into the S phase of the cell cycle. We demonstrated that Notch ic activates cyclin D1 transcription. We wanted to determine if Notch ic is able to affect components of the cell cycle machinery that act downstream of cyclin D1 and, specifically, if it is able to induce cells to progress into the cell cycle. We measured CDK2 activity, which is induced in late G 1 and commits cells to entry into the S phase. Following serum deprivation for 48 h, cells were treated in 0.1 or 10% serum in the presence or absence of 1 M OHT for 12 h. CDK2 was immunoprecipitated from precleared lysates with an anti-CDK2 antibody. Immunocomplexes were assayed for kinase activity using histone H1 as an exogenous substrate for CDK2. Hormone activation of both ER-N ic and N ic -ER chimeras resulted in induction of CDK2 activity in the absence of other serum growth factors (0.1% FBS plus OHT) (Fig. 4A) . The level of CDK2 activity detected in samples incubated in low-concentration serum in the presence of OHT was approximately threefold higher than the basal level (Fig.  4A) . In contrast, treatment of cells expressing ER with OHT in 0.1% serum did not result in CDK2 activation above the basal level (Fig. 4A) . Treatment with serum resulted in CDK2 activity approximately threefold above background in all the RKE cell lines. However, no significant difference was detected in samples incubated in the presence or absence of OHT in 10% serum (Fig. 4A) . These results indicate that Notch ic proteins can play a critical role in the regulation of the cell cycle through induction of CDK2 activity, independently of other serum-derived mitogenic signals.
In order to determine if Notch ic promotes entry into S ic -ER chimeras increased DNA synthesis in the presence of serum. In the clonal line expressing the N ic -ER chimera, the level of DNA synthesis in the presence of OHT was approximately 50% higher than the level detected in the absence of hormone, in both 5 and 10% FBS (Fig. 4B, right panels) . In low-concentration serum (0.1% FBS), OHT had a modest effect on [ 3 H]thymidine incorporation but the level of DNA synthesis was not significantly higher than the level detected in the absence of hormone (Fig. 4B, top right panel) . In the control clonal line expressing ER alone, the addition of hormone had no effect on DNA synthesis. The levels of [ 3 H]thymidine incorporation were similar in the presence and in the absence of OHT at each time point in all concentrations of serum (Fig. 4B, left panels) . Since the cells were seeded at 80% confluence, at about 24 h postinduction the cells expressing ER alone reached a plateau in the level of [ 3 H]thymidine incorporation, indicating that they were contact inhibited in 5% FBS with and without OHT and in 10% FBS with OHT (Fig. 4B, left panels) . In contrast, cells expressing the N ic -ER chimera were not contact inhibited and incorporated an increasing amount of [ 3 H]thymidine over time in 5 and 10% FBS (Fig. 4B, right panels) . Our data indicate that the activation of Notch ic -ER promotes the entry into the S phase of the cell cycle. Furthermore, cells expressing the ER were quiescent in the absence of serum, as they did not incorporate [ 3 H]thymidine above the basal level observed for synchronized cells in 0.1% FBS (Fig. 4B, left panel) , indicating that E1A, in our experimental system, is not sufficient to drive cells into the cell cycle.
CSL binds to the cyclin D1 promoter. In order to define the mechanism of induction of cyclin D1 mRNA mediated by Notch ic , we searched for possible regulatory elements related to the Notch signal transduction pathway in the cyclin D1 promoter. We identified a putative CSL binding site located at position Ϫ513 in the human cyclin D1 promoter (GenBank accession no. Z29078) (17) and at position Ϫ767 in the rat cyclin D1 promoter (GenBank accession no. AF148946) (28) . A schematic representation of the human and rat cyclin D1 promoter with binding sites for transcription factors as described in the literature is shown in Fig. 5A . The sequence of the putative CSL binding site is GCTGAGAT; this sequence is different from the consensus sequence for the high-affinity CSL binding site (GTGGGAA) previously described. However, a similar sequence, GCTGAGAA, has been identified in the human ␤-globin locus control region, which has been demonstrated to be an authentic CSL binding site (31) .
We examined the ability of CSL to bind the identified sequences by EMSA. The sequences of the wt and mut oligonucleotides used in the EMSA analysis are shown in Fig. 5A and are described in Materials and Methods. Total cell lysates were prepared from 293T cells transiently transfected with an expression vector encoding HA-tagged CSL (CSL-HA). Immunoblotting was used to show specific expression of CSL in 293T cells transfected with the vector encoding CSL-HA (Fig. 5B) . A protein-DNA complex containing CSL was identified when the radiolabeled wt D1 oligonucleotides were incubated with lysates from CSL-HA-transfected 293T cells. The complex was specifically supershifted by preincubation of the cell lysates with an anti-HA tag-specific antibody (Fig. 5C ) and was formed by both the human and the rat wt D1 oligonucleotides. In contrast, no bands corresponding to the CSL-DNA complex were detected in samples incubated with the mut sequences (Fig. 5C) .
In order to demonstrate the specificity of CSL binding to the human and rat cyclin D1 promoter, we preincubated lysates from 293T cells expressing GFP or CSL-HA with different antibodies prior to incubating them with the wt or mut labeled oligonucleotides. The CSL-DNA complex was detectable only in lysates from cells expressing CSL-HA and was specifically supershifted only by anti-CSL and anti-HA tag antibodies (Fig.  6A) , and an anti-CDK4 antibody did not supershift the CSL-DNA complex (Fig. 6A) . Furthermore, the complex was not detected in lysates from cells expressing GFP or when cells were incubated with the mut oligonucleotides. For competition analysis, 60 fmol of the radiolabeled wt D1 oligonucleotides was incubated in the presence of increasing amounts (50-and 200-fold excesses) of the unlabeled competitor oligonucleotides indicated in Fig. 6B . Increasing concentrations of the unlabeled wt D1 oligonucleotide proportionally decreased the formation of the complex, and a 50-fold molar excess of the wt JK3X oligonucleotide completely competed its formation. In contrast, the mut oligonucleotides did not display any competitive effect on the binding of CSL to the wt D1 sequence (Fig.  6B) . Similar results were obtained for both the human and the rat D1 oligonucleotides, demonstrating that CSL binds with similar affinities to both the human and the rat sequences of the cyclin D1 promoter. The conservation of the CSL site between species indicates that CSL might play an important role in the regulation of cyclin D1 transcription.
DISCUSSION
Hormone-induced Notch ic -ER chimeras activate key components of the cell cycle machinery that regulate the G 1 /S transition. A hallmark of neoplastic transformation is the deregulation of cellular proliferation through the disruption of key components of the cell cycle machinery that control the G 1 /S transition of the cell cycle (45, 52) . Activation of transcription is an important mechanism in the regulation of several of these key factors. By examining the mRNA level of several genes that encode factors known to regulate the transition from the G 1 to the S phase, we determined that hormone-activated Notch ic -ER chimeras specifically induce cyclin D1 transcription. Our data demonstrate that hormone activation of Notch ic -ER induces cyclin D1 transcription with rapid kinetics and independently of de novo synthesis of secondary transcription factors. Moreover, serum-derived mitogens are not required for Notch ic to induce cyclin D1 mRNA expression. However, induction of cyclin D1 mRNA by serum was approximately twofold higher in the presence of OHT than in serum alone in the absence of hormone ( Fig. 1 and 2B ), indicating that Notch ic can act synergistically with serum factors to induce cyclin D1 transcription. Indeed, the regulation of cyclin D1 transcription is complex and tightly modulated. Binding sites for numerous transcription factors have been identified in the promoter of the cyclin D1 gene, and several signal transduction pathways are involved in the activation of cyclin D1 mRNA transcription (1a, 2a, 34a, 34c) . For example, transcriptional activation of cyclin D1 through mitogenic signals primarily involves the Ras-dependent pathway through MEK1-ERK and the AP1 binding site present in the cyclin D1 promoter (1, 1a, 4a, 27a) .
Cyclins control cell cycle progression by regulating the activity of cyclin-dependent kinases (CDK). Association of cyclins with specific CDK partners activates the catalytic activities of these kinases, which then phosphorylate target proteins, such as Rb, to regulate the cell cycle. Specifically, the cyclin E-CDK2 complex is active in late G 1 and is required to commit cells to S-phase entry by phosphorylating Rb and thereby, causing the release of E2F (27, 27b, 34b, 36a) . We demonstrate that hormone-activated Notch ic -ER chimeras induce CDK2 activity in the absence of serum. These data suggest that Notch ic can stimulate cells to progress into the cell cycle through the induction of cyclin D1 transcription and activation of CDK2 activity, providing the first evidence that Notch ic can affect key components of the cell cycle machinery and indicating a direct involvement of Notch proteins in the regulation of cellular proliferation. By analyzing the incorporation of [ 3 H] thymidine, we determined that the activation of Notch ic -ER increases the number of cells that initiate DNA synthesis both in full (10%) and in reduced (5%) concentrations of serum, indicating that Notch ic is able to promote cells to enter into the S phase of the cell cycle. However, hormone activation of Notch ic -ER proteins did not significantly increase DNA synthesis in 0.1% serum, suggesting that induction of cyclin D1 expression and activation of CDK2 by Notch ic in RKE cells are not sufficient to induce proliferation. RKE cells are immortalized by the adenoviral oncoprotein E1A. E1A is thought to immortalize cells by inactivating Rb and thereby causing the release of E2F, which in turn induces genes involved in the G 1 -to-S transition (38) . However, cells expressing ER alone were quiescent in the absence of serum, indicating that E1A, in our experimental system, is not sufficient to override normal cell cycle controls and induce a transition from G 1 to S. Furthermore, in 10% serum RKE cells density arrest, indicating that, although they are immortal and express E1A, RKE cells retain tight regulation of the cell cycle. Activation of Notch ic leads to a constitutive level of cyclin D1 and CDK2 activity and thereby contributes to the disruption of cell cycle control, resulting in the failure of RKE cells to withdraw from the cell cycle due to contact inhibition. However, the requirement for serum in order to promote S-phase entry by Notch ic suggests that constitutive activation of cyclin D1 and CDK2 (in addition to E1A) is not sufficient to transform cells and that other factors in serum are likely to contribute to oncogenic transformation by Notch ic . Interestingly, cells derived from mammary carcinomas induced in Notch4 ic transgenic mice require MEK and P13K activity, as indicated by the failure of these cells to form colonies in semisolid media in the presence of the inhibitors PD098059 and LY294002, respectively (12) . These results might provide a clue to the identities of the missing components required in our study. We therefore propose that to drive RKE cells into S phase and for these to become transformed, it is necessary to have cooperation among Notch ic , E1A, and the Ras pathways.
The mechanism of transformation induced by Notch ic proteins involves the activation of cyclin D1 transcription through a CSL-dependent pathway. CSL is a sequence-specific DNAbinding transcriptional regulator and is one of the principal effectors of Notch signaling. CSL acts in the nuclei of cells as a transcriptional repressor, inhibiting the transcription of genes containing CSL binding sites. It has been proposed that, following ligand activation, Notch ic translocates to the nucleus and associates with CSL, converting CSL to a transcriptional activator by displacing the corepressor complex containing SMRT, HDAC1, NcoR or CIR and HDAC2. Therefore, the formation of the Notch ic -CSL complex results in the induction of transcription of CSL target genes (35a). We have identified a CSL binding site in the cyclin D1 promoter and showed that CSL specifically binds to this sequence. Previously, we reported that transformation mediated by Notch ic proteins requires transcriptional activation (23) . Here we show that a 10-amino-acid deletion in N ic⌬2105-2114 results in the complete loss of the transcriptional activation of cyclin D1 by Notch ic . N ic⌬2105-2114 is nontransforming, and although it is able to bind CSL as well as Notch ic , it fails to activate transcription from a reporter construct containing eight copies of a CSL consensus sequence (23) . Therefore, it is likely that N ic⌬2105-2114 is missing a domain responsible for transcriptional activation. In contrast, deletion of the RAM domain in Notch ic (N ic⌬R ) results in a decreased ability of N ic⌬R to induce cyclin D1 transcription compared to that of Notch ic proteins. N ic⌬R displays a weaker ability to form foci and to activate CSL-dependent transcription than that of Notch ic (23) . In glutathione S-transferase pull-down experiments, deletion of the RAM domain is sufficient to abolish the binding of Notch ic to CSL. However, in cells transformed by versions of Notch ic⌬R we find that small fractions of Notch and CSL exist in a stable complex (S. Jeffries and A. J. Capobianco, unpublished data). Therefore, the reduced level of cyclin D1 transcription is consistent with a reduced level of binding between Notch ic and CSL. Our results suggest that, in order to induce cyclin D1 expression, Notch ic proteins must be able to bind to CSL and to activate gene transcription. We have previously shown that Notch ic -ER chimeras are able to activate transcription of a reporter construct containing eight CSL binding sites only in the presence of OHT. However, Notch ic -ER chimeras bind to CSL both in the presence and in the absence of OHT (43) . These data suggest that, in the absence of OHT, Notch ic -ER and CSL form a complex that is not transcriptionally active. Our hypothesis is that OHT may induce a conformational change in Notch ic that favors the binding to the complex of factors required for activation of transcription.
Aberrant expression of cyclin D1 has been observed in numerous human tumors, and it has recently been proposed that cyclin D1 is involved in the mechanism of transformation mediated by several different oncogenes (16, 34, 41, 45, 50) . Here we show that nontransforming Notch ic proteins fail to activate cyclin D1 transcription and that a diminished ability of N ic⌬R to transform cells is related to its diminished ability to induce cyclin D1 mRNA expression. Therefore, we propose that the oncogenic mechanism driven by Notch ic involves the disruption of the normal cell cycle control and that the induction of cyclin D1 and the activation of CDK2 play a critical role in the acquisition of the transformed state induced by Notch ic proteins.
